Dimerix Ltd SBMJF:OTCPK

*Data is delayed | Exchange | USD
Last | undefined
0.00UNCH (UNCH)
52 week range
0.00 - 0.00
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.00
  • 52 Week High0.00
  • 52 Week High Date12/18/13
  • 52 Week Low0.00
  • 52 Week Low Date12/18/13

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.00
  • 52 Week High0.00
  • 52 Week High Date12/18/13
  • 52 Week Low0.00
  • 52 Week Low Date12/18/13
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-0.02
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Dimerix Ltd

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing new therapies in areas with unmet medical needs for global markets. It is focused on developing its products, DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and Diabetic Kidney Disease and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its DMX-200 and DMX-700 are identified...
Mark Diamond
Non-Executive Chairman of the Board
Nina Webster Ph.D.
Chief Executive Officer, Managing Director, Director
Hamish George
Chief Financial Officer, Company Secretary
Address
425 Smith Street, Fitzroy
Melbourne, VIC
3065
Australia